CD274 and non-small cell lung carcinoma: Immune checkpoint blockade (ICB) therapy has been proven to be successful as a treatment for non-small cell lung cancer (NSCLC) (1, 2), and different biomarkers, such as PD-L1 expression (3), tumor mutational burden (TMB) (4, 5), and gene expression profile (GEP) (6), have been recently associated with ICB response.